Evidence map›Paper›PMID 40940713›Full record

ReviewCells2025

Calpain-1 and Calpain-2 in the Brain: What Have We Learned from 45 Years of Research?

Michel Baudry, Xiaoning Bi

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. The how and why for multiple forms of hippocampal LTP.Frontiers in synaptic neuroscience · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michel BaudryDepartment of Basic Medical Sciences, College of Dental Medicine, Western University of Health Sciences, Pomona, CA 91766, USA.
Xiaoning BiDepartment of Biomedical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.

Funding

Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsyR41NS130825 · NINDS · NEURAEGIS, INC. · PI BAUDRY, MICHEL, BI, XIAONING · 2023 to 2024
$707k
CDRMP W81XWH1910329NINDS NIH HHS R41 NS130825
6 · The paper itself

Abstract

Although the calcium-dependent proteases, calpains, were discovered more than 60 years ago, we still know very little regarding their functions, mostly because very few studies are addressing questions related to specific members of this relatively large family of cysteine proteases. The "classical calpains", calpain-1 and calpain-2, are ubiquitous and have received more attention because of the special roles they play in the brain. The authors have been studying the properties and functions of these two calpain isoforms in the brain for over 45 years, and this review will focus on what has been learned over this period of time. In particular, we will discuss the numerous studies that have led to the notion that calpain-1 and calpain-2 play opposite functions in the brain on processes ranging from neuronal survival or death, synaptic plasticity, and learning and memory to neurogenesis. Mechanisms underlying these opposite functions are starting to be understood and the findings support the notion that such opposite functions might be a general feature of these two isoforms in any type of cell. This review concludes with a discussion of the potential benefits of selective calpain-2 inhibitors for the treatment of a variety of neurological disorders.

Indexed as

BrainCalpainAnimalsHumansNeuronal PlasticityNeuronsCalpainCAPN1 protein, humanCAPN2 protein, humancytoskeletoninhibitorsneurodegenerationneurogenesisphosphorylationsignaling pathwayssynaptic plasticity

Identifiers

PMID40940713
PMCPMC12427732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.